Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

about

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Item

http://www.wikidata.org/entity/Q46479042

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@en

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@nl

type

Item

label

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@en

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@nl

prefLabel

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@en

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@nl

P1476

Patient acceptable symptom sta ...... cutaneous systemic sclerosis.

@en

P2093

Angelika Jahreis

http://www.w3.org/2001/XMLSchema#string

Christopher P Denton

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

Dinesh Khanna

http://www.w3.org/2001/XMLSchema#string

Gerhard Fierlbeck

http://www.w3.org/2001/XMLSchema#string

Helen Spotswood

http://www.w3.org/2001/XMLSchema#string

Jacob M van Laar

http://www.w3.org/2001/XMLSchema#string

Janet E Pope

http://www.w3.org/2001/XMLSchema#string

Jeffrey Siegel

http://www.w3.org/2001/XMLSchema#string

Laura Burke

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies

Evaluation of the patient acceptable symptom state (PASS) in Italian patients affected by systemic lupus erythematosus: association with disease activity indices.

Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?

Outcome measures in systemic sclerosis: an update on instruments and current research.

Minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) in total hip arthroplasty (THA) patients 1 year postoperatively.

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

P304

152-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEX396

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Riemekasten

Ulf Müller-Ladner

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29077900

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

5850780

http://www.w3.org/2001/XMLSchema#string